PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18371080-2 2008 Animals treated with dopaminergic neurotoxin 1-methyl-4-phenyl-pyridinium (MPP+) develop Parkinson"s disease (PD)-like symptoms. 1-Methyl-4-phenylpyridinium 45-73 M-phase phosphoprotein 6 Homo sapiens 75-78 21667279-4 2011 In this study, we examined whether dopamine mediates 1-methyl-4-phenylpyridinium (MPP(+))-induced toxicity in primary ventral mesencephalic (VM) neurons, an in vitro model of PD, and if so, whether the protective effects of COX-2 inhibitors on dopamine mediated MPP(+)-induced VM neurotoxicity and VM dopaminergic cell apoptosis result from the reduction of ROS. 1-Methyl-4-phenylpyridinium 53-80 M-phase phosphoprotein 6 Homo sapiens 82-85 20080185-1 2010 The toxicity caused by cell exposure to 1-methyl-4-phenylpyridinium ion (MPP(+)) is a useful model in the study of Parkinson"s disease (PD). 1-Methyl-4-phenylpyridinium 40-71 M-phase phosphoprotein 6 Homo sapiens 73-76 18507712-2 2009 The results demonstrate that exogenous administration of H(2)O(2) and 1-methyl, 4-phenyl, pyridinium ion (MPP(+)) significantly decreased cell viability in SH-SY5Y cultured cells. 1-Methyl-4-phenylpyridinium 70-104 M-phase phosphoprotein 6 Homo sapiens 106-109 17631803-1 2007 OBJECTIVE: To investigate the potential protective role of Cistanche extracts on 1-methyl-4-phenylpyridinium ion (MPP(+))-induced Parkinson"s disease (PD) cellular model, and to find out whether this effect is achieved through the regulation of growth arrest- and DNA damage-induced gene 153 (GADD153). 1-Methyl-4-phenylpyridinium 81-112 M-phase phosphoprotein 6 Homo sapiens 114-117 14649730-1 2003 cDNA microarray analysis of 1-methyl-4-phenyl-pyridinium (MPP+) toxicity (1 mM, 72 h) in undifferentiated SH-SY5Y cells identified 48 genes that displayed a signal intensity greater than the mean of all differentially expressed genes and a two-fold or greater difference in normalized expression. 1-Methyl-4-phenylpyridinium 28-56 M-phase phosphoprotein 6 Homo sapiens 58-61 14529466-1 2003 This review focuses on the mechanisms of action and the injurious effect of complex I inhibitors, of which 1-methyl-4-phenylpyridinium ion (MPP(+)) is a well studied example. 1-Methyl-4-phenylpyridinium 107-138 M-phase phosphoprotein 6 Homo sapiens 140-143 8848200-1 1995 We measured beta-carbolinium cations (BC+s) endogenous analogs of the N-methyl-4-phenylpyridinium ion (MPP+), in the lumbar CSF of 22 patients with idiopathic Parkinson"s disease (PD) and 11 age-matched controls without any symptoms of parkinsonism. 1-Methyl-4-phenylpyridinium 70-97 M-phase phosphoprotein 6 Homo sapiens 103-106 8820906-0 1996 Uptake of 1-methyl-4-phenylpyridinium ion (MPP+) and ATP content in synaptosomes. 1-Methyl-4-phenylpyridinium 10-41 M-phase phosphoprotein 6 Homo sapiens 43-46 8820906-1 1996 Symptoms such as those in Parkinson"s disease are known to be induced by the neurotoxin, 1-methyl-4-phenylpyridinium (MPP+). 1-Methyl-4-phenylpyridinium 89-116 M-phase phosphoprotein 6 Homo sapiens 118-121 10601867-0 2000 The D-loop structure of human mtDNA is destabilized directly by 1-methyl-4-phenylpyridinium ion (MPP+), a parkinsonism-causing toxin. 1-Methyl-4-phenylpyridinium 64-91 M-phase phosphoprotein 6 Homo sapiens 97-100 9914521-0 1999 1-Methyl-4-phenylpyridinium ion (MPP+) selectively inhibits the replication of mitochondrial DNA. 1-Methyl-4-phenylpyridinium 0-27 M-phase phosphoprotein 6 Homo sapiens 33-36 9914521-1 1999 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine is known to cause Parkinsonism in its neurotoxic form, 1-methyl-4-phenylpyridinium ion (MPP+). 1-Methyl-4-phenylpyridinium 100-127 M-phase phosphoprotein 6 Homo sapiens 133-136 8276076-1 1993 Using a modified microdialysis procedure, we confirmed that intrastriatal administration of 1-methyl-4-phenylpyridinium ion (MPP+) induced a sustained overflow of dopamine accompanied by increased formation of hydroxyl free radicals (.OH) as reflected by salicylate hydroxylation. 1-Methyl-4-phenylpyridinium 92-123 M-phase phosphoprotein 6 Homo sapiens 125-128 8585613-5 1995 We also found that MPP+ (1-methyl-4-phenyl-pyridinium species), which is accumulated actively by platelets, inhibited [3H]DHR specific binding in a concentration-dependent manner. 1-Methyl-4-phenylpyridinium 25-53 M-phase phosphoprotein 6 Homo sapiens 19-22 33496570-2 2021 The discovery that the synthetic chemical, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-derived N-methyl-4-phenylpyridinium (MPP+), recapitulates major pathophysiological characteristics of PD in humans and other mammals has provided the strongest support for this possibility; however, several key aspects of the mechanism remain unclear. 1-Methyl-4-phenylpyridinium 103-130 M-phase phosphoprotein 6 Homo sapiens 132-135 2022343-0 1991 Theoretical studies on mechanism of MPTP action: ET interference by MPP+ (1-methyl-4-phenylpyridinium) with mitochondrial respiration vs. oxidative stress. 1-Methyl-4-phenylpyridinium 74-101 M-phase phosphoprotein 6 Homo sapiens 68-71 2022343-1 1991 This report demonstrates that ease of electron uptake by 1-methyl-4-phenylpyridinium (MPP+), apparently the active agent derived from MPTP, is influenced by conformation of the phenyl ring. 1-Methyl-4-phenylpyridinium 57-84 M-phase phosphoprotein 6 Homo sapiens 86-89 34748128-3 2022 MPP+ (1-methyl-4-phenylpyridinium)-treated SH-SY5Y cells was used as an in vitro cellular PD model. 1-Methyl-4-phenylpyridinium 6-33 M-phase phosphoprotein 6 Homo sapiens 0-3 34352280-3 2021 In this study, we attempted to determine the neuroprotective effects of methylene blue (MB) against 1-methyl-4-phenylpyridinium (MPP+)-induced neurotoxicity, and to elucidate its action mechanism. 1-Methyl-4-phenylpyridinium 100-127 M-phase phosphoprotein 6 Homo sapiens 129-132 8310426-1 1993 MPP+ (1-methyl-4-phenylpyridinium), a dopaminergic neurotoxin that provides the best available experimental model of Parkinson"s disease, is selectively concentrated in dopamine neurons by the dopamine transporter (DAT). 1-Methyl-4-phenylpyridinium 6-33 M-phase phosphoprotein 6 Homo sapiens 0-3 1543708-0 1992 Enhancement of the uptake of 1-methyl-4-phenylpyridinium ion (MPP+) in mitochondria by tetraphenylboron. 1-Methyl-4-phenylpyridinium 29-60 M-phase phosphoprotein 6 Homo sapiens 62-65 1543708-1 1992 The uptake of 1-methyl-4-phenylpyridinium (MPP+) by intact mitochondria was measured by an electrode sensitive to MPP+. 1-Methyl-4-phenylpyridinium 14-41 M-phase phosphoprotein 6 Homo sapiens 43-46 1543708-1 1992 The uptake of 1-methyl-4-phenylpyridinium (MPP+) by intact mitochondria was measured by an electrode sensitive to MPP+. 1-Methyl-4-phenylpyridinium 14-41 M-phase phosphoprotein 6 Homo sapiens 114-117 34776632-8 2021 In order to investigate the potential neuroprotective effect of BCA, human SH-SY5Y cells were treated with MPP+ (1-methyl-4-phenylpyridinium) to induce PD associated cell death and cytotoxicity. 1-Methyl-4-phenylpyridinium 113-140 M-phase phosphoprotein 6 Homo sapiens 107-110 34773593-4 2021 1-Methyl-4-phenylpyridinium (MPP +)-induced SK-N-SH cells were used to conduct expression and function analyses. 1-Methyl-4-phenylpyridinium 0-27 M-phase phosphoprotein 6 Homo sapiens 29-32 34642296-6 2021 In neuronal Lund human mesencephalic (LUHMES) cells, all seven SIRTs were substrates for autophagy and showed an accelerated autophagy-dependent degradation upon 1-methyl-4-phenylpyridinium (MPP+) mediated oxidative insults in vitro, whereas the proteasome did not contribute to the removal of oxidized SIRTs. 1-Methyl-4-phenylpyridinium 162-189 M-phase phosphoprotein 6 Homo sapiens 191-194 35279586-3 2022 1-methyl-4-phenyl pyridine (MPP+) induced SK-N-SH cells were used to construct PD cell models in vitro. 1-Methyl-4-phenylpyridinium 0-26 M-phase phosphoprotein 6 Homo sapiens 28-31 3132652-0 1988 Accumulation of N-methyl-4-phenylpyridinium ion (MPP+) in human melanoma cell line, HMV-I and -II. 1-Methyl-4-phenylpyridinium 16-43 M-phase phosphoprotein 6 Homo sapiens 49-52 3132652-1 1988 N-Methyl-4-phenylpyridinium ion (MPP+) was found to be accumulated in human melanoma cell lines, HMV-I and -II, which originate from human melanoma and differentiate into subclones, HMV-I and -II. 1-Methyl-4-phenylpyridinium 0-27 M-phase phosphoprotein 6 Homo sapiens 33-36 33978902-2 2021 Parkinson"s disease (PD) is characterized by the gradual degeneration of dopaminergic neurons in the substantia nigra of the midbrain, and has previously been modelled in-vitro through the specific neurotoxic activity of 1-methyl-4-phenylpyridinium (MPP+) on dopaminergic neurons. 1-Methyl-4-phenylpyridinium 221-248 M-phase phosphoprotein 6 Homo sapiens 250-253 32611232-1 2021 This research aims to explore the function of DOR in 1-methyl-4-phenylpyridinium (MPP+)-induced Parkinson"s disease model cell SH-SY5Y. 1-Methyl-4-phenylpyridinium 53-80 M-phase phosphoprotein 6 Homo sapiens 82-85 32333925-4 2021 In this study, we found that AST treatment significantly not only abolished the cell viability inhibition and apoptosis promotion induced by 1-methyl-4-phenylpyridinium (MPP+) in SH-SY5Y cells via inhibiting endoplasmic reticulum (ER) stress, but also reversed the MPP + caused dysregulation of miR-7 and SNCA expression. 1-Methyl-4-phenylpyridinium 141-168 M-phase phosphoprotein 6 Homo sapiens 170-173 32275913-1 2021 1-methyl-4-phenylpyridinium ion (MPP+) is widely used to induce a cellular model of Parkinson"s disease (PD) in dopaminergic cell lines. 1-Methyl-4-phenylpyridinium 0-31 M-phase phosphoprotein 6 Homo sapiens 33-36 33634378-5 2021 Our present study showed that 1-methyl-4-phenylpyridinium (MPP+) decreased cell viability, GPX4, and Trx-1, which were reversed by Ferrostatin-1 (Fer-1) in PC 12 cells and SH-SY5Y cells. 1-Methyl-4-phenylpyridinium 30-57 M-phase phosphoprotein 6 Homo sapiens 59-62 32808542-3 2020 A PD model was constructed using SH-SY5Y cells induced by 1-methyl-4-phenylpyridinium (MPP+) in vitro and mice treated by 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in vivo. 1-Methyl-4-phenylpyridinium 58-85 M-phase phosphoprotein 6 Homo sapiens 87-90 33472166-4 2021 In SH-SY5Y cell line, overexpression of CHIP improved the cell viability and increased the ATP levels upon treatment with 1-methyl-4-phenylpyridinium (MPP+). 1-Methyl-4-phenylpyridinium 122-149 M-phase phosphoprotein 6 Homo sapiens 151-154 33414358-1 2020 MPP+ (1-methyl-4-phenylpyridinium)-induced dopaminergic neuronal cell apoptosis is associated with sphingosine kinase 1 (SphK1) inhibition. 1-Methyl-4-phenylpyridinium 6-33 M-phase phosphoprotein 6 Homo sapiens 0-3 33457479-1 2021 1-Methyl-4-phenylpyridinium (MPP+)-treated human neuroblastoma SH-SY5Y cells have been generally accepted as a cellular model for Parkinson"s disease. 1-Methyl-4-phenylpyridinium 0-27 M-phase phosphoprotein 6 Homo sapiens 29-32 33260513-6 2020 In this study, the neuroprotective potential of teaghrelin against PD was explored in a cell model in which human neuroblastoma SH-SY5Y cells were treated with the mitochondrial toxin 1-methyl-4-phenylpyridinium (MPP+). 1-Methyl-4-phenylpyridinium 184-211 M-phase phosphoprotein 6 Homo sapiens 213-216 29575151-5 2018 Human neuroblastoma cell line SH-SY5Y was pretreated with 1-Methyl-4-phenylpyridinium (MPP+). 1-Methyl-4-phenylpyridinium 58-85 M-phase phosphoprotein 6 Homo sapiens 87-90 32713934-4 2020 MATERIAL AND METHODS The optimal concentration of MPP+ (1-methyl-4-phenylpyridinium ion) was initially determined to construct a PD cell model. 1-Methyl-4-phenylpyridinium 56-83 M-phase phosphoprotein 6 Homo sapiens 50-53 32442477-8 2020 1-methyl-4-phenylpyridinium ion (MPP+)-treated SK-N-SH cells were used as an in vitro model of PD. 1-Methyl-4-phenylpyridinium 0-27 M-phase phosphoprotein 6 Homo sapiens 33-36 31228597-4 2019 Human neuroblastoma cell line SH-SY5Y was treated with 1-Methyl-4-phenylpyridinium (MPP+) to mimic PD model in vitro. 1-Methyl-4-phenylpyridinium 55-82 M-phase phosphoprotein 6 Homo sapiens 84-87 32577946-2 2020 However, the roles of H2S in 1-methyl-4-phenylpyridinium ion (MPP+)-treated SH-SY5Y cells with the involvement of reactive oxygen species-nitric oxide (ROS-NO) signaling pathway in PD remain unclear. 1-Methyl-4-phenylpyridinium 29-60 M-phase phosphoprotein 6 Homo sapiens 62-65 32215836-4 2020 In the present study, it was aimed to investigate ameliorative effects of hexagonal boron nitride nanoparticles (hBNs) against toxicity of 1-methyl-4-phenylpyridinium (MPP+) in experimental PD model. 1-Methyl-4-phenylpyridinium 139-166 M-phase phosphoprotein 6 Homo sapiens 168-171 29030221-4 2018 In this study, we found that miR-210-3p is involved in the regulation of BDNF production by 1-methyl-4-phenylpyridinium (MPP+). 1-Methyl-4-phenylpyridinium 92-119 M-phase phosphoprotein 6 Homo sapiens 121-124 29293433-3 2018 In the present study, we investigated the protective effects of ZSCF extract against 1-methyl-4-phenylpyridinium (MPP+) induced neurotoxicity in SH-SY5Y cell lines. 1-Methyl-4-phenylpyridinium 85-112 M-phase phosphoprotein 6 Homo sapiens 114-117 28442376-1 2017 Intrastriatal injection of 1-methyl-4-phenylpyridinium (MPP+) is considered a model to reproduce some biochemical alterations observed in Parkinson"s disease (PD) patients. 1-Methyl-4-phenylpyridinium 27-54 M-phase phosphoprotein 6 Homo sapiens 56-59 26411459-8 2016 The results indicated that rhFGF8b prevented necrosis and apoptosis of 1-METHYL-4-phenyl pyridine (MPP(+)) treated PC12 cells. 1-Methyl-4-phenylpyridinium 71-97 M-phase phosphoprotein 6 Homo sapiens 99-102 25061051-7 2015 These findings were verified in an in vitro study showing that 1-methyl-4-phenylpyridinium (MPP+) treatment leads to suppression of EPCR along with reduction of protein C activation in human primary endothelial cells. 1-Methyl-4-phenylpyridinium 63-90 M-phase phosphoprotein 6 Homo sapiens 92-95 23644103-1 2013 OBJECTIVE: To investigate the role of calcium dyshomeostasis in 1-methyl-4-phenylpyridinium ion (MPP+)-induced apoptosis of human neuroblastoma SH-SY5Y cells. 1-Methyl-4-phenylpyridinium 64-95 M-phase phosphoprotein 6 Homo sapiens 97-100 29270589-2 2017 Recently a new approach has been used to develop Parkinsonian monkeys with unilateral intracerebroventricular injections of 1-methyl-4-phenylpyridinium ion (MPP+). 1-Methyl-4-phenylpyridinium 124-151 M-phase phosphoprotein 6 Homo sapiens 157-160 26413876-3 2015 Extrapolations of data obtained using MPTP-based parkinsonism models to human disease are common; however, the precise mechanism by which MPTP is converted into its active neurotoxic metabolite, 1-methyl-4-phenyl-pyridinium (MPP(+)), has not been fully elucidated. 1-Methyl-4-phenylpyridinium 195-223 M-phase phosphoprotein 6 Homo sapiens 225-228 25645943-3 2015 Commonly used in animal models of PD, MPTP can metabolize to 1-methyl-4-phenylpyridinium (MPP(+)); however, the detailed mechanism through which MPP(+) causes neuronal cell death remains undetermined. 1-Methyl-4-phenylpyridinium 61-88 M-phase phosphoprotein 6 Homo sapiens 90-93 25645943-3 2015 Commonly used in animal models of PD, MPTP can metabolize to 1-methyl-4-phenylpyridinium (MPP(+)); however, the detailed mechanism through which MPP(+) causes neuronal cell death remains undetermined. 1-Methyl-4-phenylpyridinium 61-88 M-phase phosphoprotein 6 Homo sapiens 145-148 23370975-3 2013 In this study, KLF4 was found to be increased in both a time-dependent manner and a dose-dependent manner in response to the incubation with 1-methyl-4-phenylpyridinium (MPP+) in human dopamine neuroblastoma M17 cells, suggesting a potential role in MPP + -induced neurotoxicity. 1-Methyl-4-phenylpyridinium 141-168 M-phase phosphoprotein 6 Homo sapiens 170-173 23370975-3 2013 In this study, KLF4 was found to be increased in both a time-dependent manner and a dose-dependent manner in response to the incubation with 1-methyl-4-phenylpyridinium (MPP+) in human dopamine neuroblastoma M17 cells, suggesting a potential role in MPP + -induced neurotoxicity. 1-Methyl-4-phenylpyridinium 141-168 M-phase phosphoprotein 6 Homo sapiens 250-253 23411763-3 2013 The mitochondrial toxicant 1-methyl-4-phenylpyridinium (MPP(+)) shows a highly selective toxicity to dopaminergic neurons. 1-Methyl-4-phenylpyridinium 27-54 M-phase phosphoprotein 6 Homo sapiens 56-59